Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPuLCE phase II study of EBX-102 in liver cirrhosis
ISRCTN11352030Phase 2Completed
- Sponsor
- EnteroBiotix
- Start
- May 2023
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
01
Overview
Phase 2, randomised, double-blind trial of EBX-102 in Cirrhosis (4 arms), sponsored by EnteroBiotix. Primary endpoint: Safety and tolerability of EBX-102. Started May 2023; status: completed.
02
Drugs
EBX-102
03
Conditions
Cirrhosis
Beyond the preview
Go deeper on ISRCTN11352030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN11352030.